Once-yearly zoledronic acid in hip fracture prevention by Demontiero, Oddom & Duque, Gustavo
© 2009 Demontiero and Duque, publisher and licensee Dove Medical Press Ltd. This is an Open Access 
article which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Interventions in Aging 2009:4 153–164 153
REVIEW
Once-yearly zoledronic acid in hip fracture 
prevention
Oddom Demontiero
Gustavo Duque
Aging Bone Research Program, 
Nepean Clinical School, University 
of Sydney, Penrith, NSW, Australia; 
Department of Geriatric Medicine, 
Nepean Hospital, Penrith, NSW, 
Australia
Correspondence: Gustavo Duque 
Nepean Clinical School, Level 5, 
South Block, Nepean Hospital, 
Penrith, NSW, Australia 2750
Tel +61 2 47344279  
Fax +61 2 47341817
Email gduque@med.usyd.edu.au
Abstract: Osteoporosis is an escalating global problem. Hip fractures, the most catastrophic 
complication of osteoporosis, continue to cause signiﬁ  cant mortality and morbidity despite 
increasing availability of effective preventative agents. Among these agents, oral bisphosphonates 
have been the ﬁ  rst choice for the treatment and prevention of osteoporotic fractures. However, 
the use of oral bisphosphonates, especially in the older population, has been limited by their 
side effects and method of administration thus compromising their persistent use. The resultant 
low adherence by patients has undermined their full potential and has been associated with an 
increase in the incidence of fragility fractures. Recently, annual intravenous zoledronic acid 
(ZOL) has been approved for osteoporosis. Randomized controlled trials have demonstrated 
ZOL to be safe, have good tolerability and produce signiﬁ  cant effect on bone mass and micro-
architecture. Adherence has also been shown to be better with ZOL. Furthermore two large 
trials ﬁ  rmly demonstrated signiﬁ  cant anti-osteoporotic effect (∼59% relative risk reduction of 
hip fractures) and mortality beneﬁ  t (28% reduction in mortality) of ZOL in older persons with 
recent hip fractures. In this review, we report the current evidence on the use of ZOL for the 
prevention of hip fractures in the elderly. We also report the pharmacological characteristics 
and the advantages and disadvantages of ZOL in this particular group.
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Introduction
Osteoporosis is a disease associated with low bone mass, which predisposes to fractures.1,2 
Osteoporosis is also a major public health problem that represents a signiﬁ  cant burden for 
health care budgets due to the increasing prevalence of fractures and disability.3 Aging is 
the most important risk factor for osteoporosis4,5 being highly prevalent in both elderly 
men and women with its incidence expected to increase in the upcoming years.6,7
Although all fractures not associated with trauma in older adults should be 
interpreted as osteoporotic fractures,8 hip fractures represent the most typical and 
catastrophic events associated with osteoporosis in older adults. In fact, hip fractures 
are considered a predictor of mortality in both institutionalized and ambulatory older 
persons. With hip fractures, most deaths occur in the ﬁ  rst 3 to 6 months following the 
event, of which 20% to 30% are causally related to the fracture event itself.9 Women 
with hip fractures have mortality rates 10% to 20% greater than expected for their age 
within the ﬁ  rst year10 and this excess mortality persists for several years after the hip 
fracture.11 In fact, a white woman when sustaining a hip fracture at age 70 has an excess 
mortality of 3%, 4%, 7% and 13% at 1, 2, 5 and 10 years after injury, respectively.11
Unfortunately, a signiﬁ  cant proportion of elderly patients who have suffered a 
hip fracture do not receive further treatment for osteoporosis.12–17 Considering that 
the occurrence of a hip fracture is a predictor of new fractures,18–21 mortality9,22–24 and 
disability,25 a more pro-active and effective therapeutic approach should be encouraged 
in all elderly patients after presenting with hip fractures.Clinical Interventions in Aging 2009:4 154
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There have been additional therapeutic agents available 
in the management of osteoporosis in recent years.26–28 
New medications have shown to be effective for primary 
and secondary prevention of osteoporotic fractures.27,28 In 
addition, less frequent dosing of bisphosphonates, a group 
of medications that constitute the mainstay of treatment for 
osteoporosis, have demonstrated their impact by improving 
compliance, a major limitation for effective osteoporosis 
treatment in the older population.28
Amongst the bisphosphonates, an annual dose of 
zoledronic acid (ZOL) has been recently proven as an 
effective approach for the management of osteoporosis.29,30 
This intravenous dose has several advantages over other 
bisphosphonates, compliance being the most important. In 
this review, we will summarize the pharmacological charac-
teristics of ZOL and the recent evidence on annual ZOL in 
primary and secondary prevention of hip fractures focusing 
on the evidence in the older population.
Mechanisms of action 
of zoledronic acid
Pharmacodynamics
Bisphosphonates are pyrophosphate analogs with high 
afﬁ  nity for hydroxyapatite and bind directly to mineralized 
bone.26,31 The bound bisphosphonate blocks the surface of 
bone and prevents osteoclasts from binding to the resorption 
surface. The bisphosphonates also inhibit osteoclastic activ-
ity, reduce the lifespan of the osteoclasts and alters the bone 
or bone mineral to reduce the rate of dissolution.32
There are two classes of bisphosphonates: the second 
generation that contains nitrogen in either an alkyl chain 
(alendronate, pamidronate and ibandronate) or within a het-
erocyclic ring (risedronate and ZOL) and the earlier genera-
tion that does not (etidronate and clodronate). Those without 
the nitrogen side chain have low antiresorptive potency and 
works by being incorporated into molecules of adenosine 
triphosphate (ATP). Subsequent intracellular accumulation of 
these nonhydrolyzable ATP analogues inhibit ATP-dependent 
cellular processes, thus inducing osteoclast-apoptosis.26,33,34 
The more potent nitrogen containing bisphosphonates affect 
osteoclast activity and survival through the inhibition of 
the enzymes within the mevalonate pathway, the biosyn-
thetic pathway for cholesterol and isoprenoid lipids such as 
farnesyl pyrophosphate (FPP) and geranylgeranyl diphosphate 
(GGPP). The key enzyme is thought to be FPP synthase.36 
Biochemical studies31,36–38 have demonstrated that ZOL 
and other nitrogen-containing bisphosphonates inhibit FPP 
synthase, thus preventing the synthesis of FPP and GGPP, 
which are necessary for prenylation of small guanosine 
triphosphate (GTP)-binding proteins in osteoclasts. The loss 
of these prenylated proteins is associated with decreased 
osteoclast activity and apoptosis.39,40
The mechanism of apoptosis in osteoclasts was further 
studied by Benford et al.39 Osteoclast apoptosis was associated 
with activation of caspase-3–like proteases, loss of mitochon-
drial membrane potential and classic morphologic changes. 
Of the bisphosphonates studied (risedronate, pamidronate, 
clodronate, etidronate, tiludronate, alendronate, and ZOL), 
ZOL was the most potent inhibitor of FPP synthase41 and 
caused the greatest increase in caspase-3–like activity at 
48 hours after treatment. This order of potency in inhibiting 
FPP synthase (ZOL  risedronate  ibandronate  
alendronate) (Figure 1) closely matched the order of anti-
resorptive potency.10 Ultimately the relative potency of dif-
ferent bisphosphonates is related to their binding afﬁ  nities 
for hydroxyapatite and their degree of inhibition of FPP 
synthase. Nancollas et al42 demonstrated that the different 
binding afﬁ  nities of various bisphosphonates correlated with 
the differences in the R2 side chain (ZOL  alendronate  
ibandronate = risedronate) (Figure 1).
In addition, ZOL may have direct effects on osteoblasts. 
Studies examining its effects on BMD, bone architecture, 
bone strength and biochemical markers of bone metabolism 
have demonstrated favorable effects which included dose-
dependent prevention of increased cortical bone porosity and 
decreased bone resorption.43,44 In vitro studies also showed 
that ZOL inhibits vitamin D3-induced calcium release and 
that at effective doses for inhibiting bone resorption, it did not 
inhibit bone mineralization to any greater degree compared 
to other bisphosphonates.38
Pharmacokinetics
ZOL is administered as a once-yearly 5-mg intravenous 
infusion over no less than 15 minutes.45 ZOL is not metabo-
lized in humans and about 40% of an IV dose of ZOL is 
eliminated unchanged via the kidney.46 The remaining 60% 
binds to bone. In vivo studies in rats showed that high levels 
of 14C-labeled ZOL ( 1.105 pmol/g) distributed widely 
throughout the axial and appendicular skeleton, mandible, 
skull, and kidney within 1 hour after IV injection.38 Bone 
concentrations remained high although levels of ZOL in 
blood and soft tissues declined to low levels (1 pmol/g) 
after a period of 8 months following administration.
A pharmacokinetic study47 showed that ZOL produced 
dose-proportional plasma concentrations that declined 
rapidly in a triphasic manner: rapid biphasic disappearance Clinical Interventions in Aging 2009:4 155
Zoledronic acid and hip fracture
from the systemic circulation followed by a long elimination 
phase with a terminal elimination half-life of 146 hours. 
Twenty-four hours after injection, plasma concentrations 
declined to 1% of the peak concentration at the end of 
infusion.
The substance is thought to have little or no capacity as 
a direct acting and/or irreversible metabolism dependent 
inhibitor of cytochrome P450 enzymes, and thus is unlikely 
to reduce the metabolic clearance of substances that are 
metabolized via the cytochrome P450 enzyme systems. 
No speciﬁ  c drug–drug interactions have been documented 
with ZOL.
The renal clearance of ZOL correlated with creatinine 
clearance. Small observed increases in AUC (0–24 hours), by 
about 30% to 40% in mild to moderate renal impairment, com-
pared to a patient with normal renal function, and lack of accumu-
lation of drug with multiple doses irrespective of renal function, 
suggest that dose adjustments of ZOL in mild (Clcr = 50–80 
mL/minute) and moderate (Clcr = 35–50 mL/minute) renal 
impairment are not necessary. In fact, a recent study by Boonen 
et al48 looking at renal safety of annual ZOL infusions in 7714 
osteoporotic postmenopausal women found that transient 
changes in renal function can occur following an annual 
ZOL infusion but, in the long term, renal function was not 
different from that in control patients. Nevertheless, as with 
other bisphosphonates, the use of ZOL in elderly patients with 
creatinine clearance 35 mL/minute is not recommended due to 
limited clinical safety data in such patients.
Safety and tolerability
Overall ZOL is safe and well tolerated when used in the 
treatment and prevention of osteoporosis. The most com-
mon adverse events observed were acute phase reactions,29 
usually characterized by ﬂ  u-like symptoms, headache, bone 
pain, arthralgias and myalgias. Most of these symptoms 
occurred within the ﬁ  rst 3 days after infusion and tended to 
resolve within several days after administration. They are 
usually easily managed with acetaminophen or ibuprofen and 
the incidence of these symptoms decreased with subsequent 
annual infusions.
Renal effects
No clinically signiﬁ  cant long-term effects of ZOL on renal 
function have been observed so far. In the HORIZON-PFT, 
there was a signiﬁ  cant increase in serum creatinine of more 
than 44 μmol/L in 1.3% of ZOL-treated patients, compared 
with 0.4% of placebo patients at 9 to 11 days post infusion. 
Within 30 days, however, the levels in more than 85% of 
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Figure 1 Compared with other bisphosphonates of the same generation, zoledronic acid has shown a higher inhibitory effect on farnesyl pyrophosphate synthase (FPP) (A) as 
well as higher afﬁ  nity for hydroxyapatite in bones (B).Clinical Interventions in Aging 2009:4 156
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patients had returned to within 44 μmol/L of pre-infusion 
values, and the remainder had returned to this level by the next 
annual follow-up. At 3 years, there was no signiﬁ  cant differ-
ence in either serum creatinine levels or creatinine clearance 
between the placebo group and ZOL group. Boonen et al48 
reported these changes testing the renal-function of 5035 
osteoporotic postmenopausal women from the HORIZON 
Pivotal Fracture Trial. They also found that two of the four 
patients in the ZOL group who suffered acute renal failure 
requiring hospitalization had baseline creatinine clearance 
of 31 mL per min. Overall, they reported the mean decrease 
in serum creatinine in these elderly patients to be similar in 
both groups, as well as the overall number of observed renal 
adverse effects.
Comparable results were reported in HORIZON-RFT;30 
the incidence of serum creatinine elevations greater than 
44 μmol/L did not differ between the ZOL and placebo groups 
(6.2% and 5.6%). The result from McClung et al49 trial is 
similar. Only 0.02% of patients in the ZOL group experienced 
a rise in serum creatinine or creatinine clearance. Furthermore 
these patients had low baseline creatinine clearance of around 
30 mL/min. At the end of 1 year the renal function recovered 
to near baseline. Reid et al50 administering various doses of 
ZOL also did not observe any signiﬁ  cant renal side effects.
Atrial ﬁ  brillation (AF)
The association with AF remains uncertain, as a causal 
relationship has not been established. In HORIZON-PFT,29 
the number of patients who had arrhythmia in the ZOL 
group (266 patients, or 6.9%) was signiﬁ  cantly higher than 
that in the placebo group (203 patients, or 5.3%; p = 0.003). 
The overall incidence of all AF adverse events was 2.4% of 
patients (94 of 3862) in the ZOL group, compared with 1.9% 
of patients (73 of 3852) in the placebo group. AF judged to 
be serious occurred in 50 patients in the ZOL group (1.3%), 
as compared with 17 patients (0.4%) in the placebo group. 
Among the 50 patients, the events occurred more than 
30 days after infusion in 47 patients. Among 559 patients 
who underwent electrocardiography, the prevalence of ZOL 
(2.1% in the ZOL group and 2.8% in the placebo group) 
and other electrocardiographic abnormalities did not differ 
signiﬁ  cantly between the study groups. Interestingly the 
HORIZON-RFT30 did not ﬁ  nd a difference in the incidence 
of AF events: 29 (2.8%) in the ZOL group versus 27 (2.6%) 
cases for the placebo group. In summary, data on the inci-
dence of AF reported in clinical trials using ZOL for fracture 
prevention is limited to only two studies. More evidence is 
required to consider whether this ﬁ  nding is just chance or 
a real side effect that should be seriously considered when 
treating old patients.
Osteonecrosis of the jaw (ONJ)
The incidence of ONJ in patients treated for osteoporosis 
using bisphosphonates is estimated to be less than 1 in 
100,000 patients.51 Although there have been case reports of 
ONJ in patients on alendronate51,52 and risedronate,53 there 
have been no reports of spontaneous ONJ in patents treated 
with ZOL. However, in HORIZON-PFT29 an independent 
adjudication committee blinded to study treatment identiﬁ  ed 
two potential cases of ONJ, one in the placebo arm and one 
in the ZOL group.
Other adverse effects
Comparable number of patients in HORIZON-PFT29 and in 
HORIZON-RFT30 had notable declines of serum calcium 
levels (to 7.5 mg/dL) after administration of ZOL; but 
no symptomatic cases of hypocalcemia were observed. It is 
possible that the loading of vitamin D and continued admin-
istration of vitamin D and calcium may mask the incidence 
of hypocalcemia or reduce its severity.
Another bone safety aspect that has been debated for 
several years is that prolonged use of bisphosphonates at high 
doses might be associated with micro fractures as described in 
animal models.54,55 These ﬁ  ndings are not clear in the clinical 
setting as the doses used in these experiments are about 6-fold 
higher than that used in humans. Furthermore a study exam-
ining micro cracks in bones of dogs receiving alendronate 
and risedronate did not show effect on mechanical properties 
despite conﬁ  rming increased micro-damage accumulation.56 
Finally, in the FLEX trial, Recker et al57 did not ﬁ  nd evidence 
of mineralization defect in bones of women who had been 
on alendronate for 10 years. Finally, no evidence associating 
ZOL and bone micro cracks has been reported.
Clinical trials with zoledronic acid
The effects of ZOL on bone mineral density (BMD) was 
investigated by Reid et al.50 They conducted a multinational 
one year study that randomized 45–80 year old postmeno-
pausal women with T-scores at the lumbar spine of less 
than –2 SD to receive either placebo or one of ﬁ  ve ZOL 
regimens: 0.25 mg, 0.5 mg, or 1 mg at 3-month intervals; a 
single 4-mg dose; or 2 doses of 2 mg administered 6 months 
apart. Although, the rate of increase tended to slow in the 
second half of the study, there were signiﬁ  cant improve-
ment in the average mean lumbar spine BMD and femoral 
neck BMD in the ZOL group compared with the placebo Clinical Interventions in Aging 2009:4 157
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group (see Table 1). In contrast, BMD at the distal radius 
responded to ZOL treatment to a lesser extent. Signiﬁ  cant 
decreases in bone turnover markers were also observed with 
the ZOL group. Markers of bone resorption reached a nadir at 
1 month; however median decreases of 65% to 83% in serum 
C-telopeptide and 50% to 69% in the urinary N-telopeptide 
(Ntx):creatinine ratio were achieved. Furthermore the decrease 
in markers of resorption tended to be dose-dependent, particu-
larly at 3 months of treatment. The incidence of adverse events 
was similar between all ZOL groups. The most commonly 
reported were myalgia and pyrexia.
Saag et al58 compared the onset of action, effects on 
bone resorption and tolerability of ZOL with alendronate. 
Postmenopausal women aged 45 to 79 years were random-
ized to receive either a single infusion of ZOL 5 mg plus 
oral placebo or weekly oral alendronate 70 mg plus a single 
placebo intravenous infusion. Women with either a femoral 
neck or lumbar spine BMD T-score of –2 or less at study 
initiation and no previous bisphosphonate use of 2 or more 
years were included.
At week 1, signiﬁ  cantly lower mean urine NTx value was 
seen in the ZOL group as opposed to the alendronate group 
(15.2 nmol bone collagen equivalents (BCE)/mmol creatinine 
and 35.5 nmol BCE/mmol creatinine, respectively). After 
this nadir, levels gradually increased but were signiﬁ  cantly 
lower than the alendronate group throughout the 24-week 
study and remained stable within the study reference range 
of premenopausal women (17.8–46.4 nmol BCE/mmol 
creatinine) from week 12 to study end. Despite comparable 
adverse events (91.3% in the ZOL group and 86.4% in the 
alendronate group) and similar premature discontinuation 
rates (8.7% in the ZOL group and 8.5% in the alendronate 
group), the majority of patients preferred the annual ZOL 
infusion to the weekly alendronate, citing convenience as 
the primary factor.
In another multicenter trial, McClung et al49 similarly 
demonstrated better adherence and preference for annual 
infusion of ZOL over 70 mg weekly of oral alendronate. 
Postmenopausal women who were receiving oral alendronate 
for at least 1 year and had lumbar spine or femoral neck BMD 
T-score values  −2.0 SD were randomized to one 15-min IV 
infusion of ZOL 5 mg plus 52 weeks of oral placebo or one 
IV infusion of placebo plus 52 weeks of oral alendronate 
70 mg. Bone marker levels decreased steadily in both 
groups and at month 12 remained in the lower half of the 
premenopausal reference range. The overall rates of adverse 
events were comparable in the 2 groups (ZOL 5 mg, 86.7%; 
alendronate 70 mg, 80.4%). The majority (78.7%) of patients 
regardless of study groups expressed preference for once 
yearly infusion over weekly oral therapy. This result suggests 
that patients could be switched from oral alendronate to ZOL 
5 mg infusion without affecting the therapeutic beneﬁ  ts of 
oral bisphosphonates. This evidence is useful in cases in 
which oral bisphosphonates are not well tolerated or when 
adherence is a major issue.
Whether the actions of a single dose of ZOL on bone 
turnover and on BMD extends beyond 12 months was recently 
investigated by Borba et al59 This was a prospective study 
evaluating the changes in bone turnover at 12 months (T12) 
and 18 months (T18). The subjects had low BMD, had at least 
one other risk factor (in all but three) and had a mean age of 
60.5 ± 16 years. Other metabolic bone diseases and past use 
of bisphosphonates were included in the exclusion criteria.
Median serum bone turnover markers levels were 
signiﬁ  cantly suppressed at T12 and continued to be sup-
pressed at T18 in comparison with baseline values. BMD 
at 12 months showed signiﬁ  cant increase at the lumbar 
spine (LS) which was sustained at T18 (Table 1). A modest 
increase in total hip BMD was also evident and maintained 
at T18. The results of this study suggest that there may be a 
role of extending the time between infusions of ZOL beyond 
12 months without losing efﬁ  cacy and thereby possibly 
reducing costs and increasing adherence even further.
The long-term safety and efﬁ  cacy of ZOL in women 
with postmenopausal osteoporosis was further evaluated 
by Devogelaer et al.60 This extension of a previous study50 
was composed of 2 consecutive open-label, 2-year periods. 
Women who entered the ﬁ  rst extension study received ZOL 
0.5 mg every 3 months; the others were administered ZOL 
1 mg every 3 months. Patients who entered the second 
extension study received either calcium only or ZOL 4 mg. 
Patients received treatment for either 2, 3, or 5 years. The 
efﬁ  cacy of ZOL was measured by DEXA assessment of BMD 
at the proximal femur, lumbar spine, distal radius, and total 
body. BMD was found to increase in all three subgroups by 
the end of the 5-year total study period.
Arthralgia was the most commonly reported adverse 
event and 8 patients experienced serious adverse events, with 
7 of the 15 total events reported as cardiovascular related. 
Interpretation of this study is however relatively limited due 
to the open-label design, small treatment groups, and lack of 
clariﬁ  cation of cardiovascular adverse events.
Zoledronic acid and hip fractures
Hip fractures are highly prevalent in older osteoporotic 
patients. However, despite a myriad of literature on Clinical Interventions in Aging 2009:4 158
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osteoporosis and its treatment, only a number of trials have 
assessed hip fractures as primary outcomes.61 In the case 
of ZOL, very few studies have been pursued looking at 
its effectiveness on primary and secondary prevention of 
hip fractures (Table 1) and just a few of them have looked 
speciﬁ  cally in older populations.
Recently, ZOL impact on re-fracture reduction was 
demonstrated in The HORIZON (Health Outcomes and 
Reduced Incidence with ZOL Once Yearly) Pivotal Fracture 
trial.29 This is the ﬁ  rst trial to speciﬁ  cally evaluate the effects of 
ZOL on fractures. This double-blind, placebo-controlled trial 
enrolled 7765 postmenopausal women (mean age, 73 years) 
with conﬁ  rmed osteoporosis and evidence of clinical fractures. 
Prior to randomization, patients were stratiﬁ  ed according to 
their concomitant use of osteoporosis medications (raloxifene, 
calcitonin and hormone replacement therapy but not other 
bisphosphonates). 3889 were randomly assigned to receive 
a single 15-minute infusion of ZOL (5 mg) and 3876 were 
assigned to receive placebo at baseline, at 12 months, and at 
24 months. The patients were followed for 3 years. All patients 
received oral daily calcium (1000–1500 mg) and vitamin 
D (400–1200 IU). Primary end points were new vertebral frac-
tures (in patients not taking concomitant osteoporosis medica-
tions) and hip fractures (in all patients). Secondary end points 
included BMD, bone turnover markers, and safety outcomes.
In women not receiving concomitant medications, ZOL 
was found to reduce the risk of morphometric vertebral 
fracture by 70% during the 3-year study period, as compared 
with placebo (3.3% in the ZOL group vs 10.9% in the placebo 
group; absolute risk reduction of 7.6%) and from both arms of 
treatment there was a reduction in the risk of hip fracture of 
41% (1.4% in the ZOL group vs 2.5% in the placebo group; 
ARR 1.1%) (Figure 2A).
Secondary outcomes also favored the ZOL group includ-
ing a 33% reduction in any clinical fractures (8.4% vs 12.8%), 
77% reduction in clinical vertebral fractures (0.5% vs 2.6%) 
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and multiple vertebral fractures (0.2% vs 2.3%) and 25% in 
nonvertebral fractures (8.0% vs 10.7%). As compared with 
placebo, ZOL was also associated with a signiﬁ  cant improve-
ment in BMD and bone metabolism markers. BMD was 
increased at the total hip (6.02%), lumbar spine (6.71%) and 
the femoral neck (5.06%). Tolerability was acceptable with 
81% of patients receiving the maximum of three infusions. 
Retention rates were comparable with 2.1% of the ZOL group 
discontinuing treatment due to adverse events compared with 
1.8% in the placebo group.
Adverse events, including change in renal function were 
similar in the two study groups. Interestingly, there was 
an inexplicable statistically signiﬁ  cant increase in serious 
AF in the ZOL group compared with the placebo group 
(50 vs 20 patients, respectively), which occurred more than 
30 days after infusion in 47 women in the treatment group. 
This suggests that it may not be related to the acute infusions. 
Hypocalcemia as a cause was deemed unlikely from the regular 
evaluation of electrolyte changes. The author reported that 
there were signiﬁ  cant differences between study groups in the 
change in serum calcium from the level before the ﬁ  rst infu-
sion of ZOL to the level 9 to 11 days after the infusion, but the 
magnitude of the difference was relatively small (a reduction of 
0.2 ± 0.5 mg/dL in the ZOL group vs an increase of 0.03 ± 0.4 
in the placebo group). This difference was not evident at 
12 months, and no signiﬁ  cant changes occurred with subse-
quent doses. Furthermore, the change in calcium levels after 
the ﬁ  rst infusion did not differ between women with AF and 
those without AF. Over the 3 years of the study, mean serum 
calcium levels increased in both study groups, although the 
mean increase was slightly larger in the placebo group than in 
the ZOL group. Magnesium and potassium levels did not differ 
between the two study groups and were similar in women with 
and those without AF. It should be noted also that episodes 
of AF did not cluster in time immediately after any infusion, 
when serum electrolytes are most affected. Taken together, 
these ﬁ  ndings suggest a possible alternative explanation.
Finally, there are some features of this study that make it 
unique in terms of the population studied. Although an active 
comparator would be of great clinical interest, the numbers 
required for such a trial to demonstrate equivalent or supe-
rior fracture risk reductions would be difﬁ  cult to obtain and 
possibly prohibitive. Instead, to simulate reality, the protocol 
speciﬁ  ed that patients had to be unable or unwilling to take 
oral bisphosphonates and all women were counseled on the 
risk of fracture and the availability of approved osteoporosis 
medications. Another allowance that mirrors clinical reality 
was that women who were receiving nonbisphosphonate 
treatments for osteoporosis (including hormone therapy, 
raloxifene, and calcitonin) were included (“stratum 2”), 
and all patients were free to begin any of these treatments 
during the study while continuing to receive the study treat-
ment. Furthermore, the researchers monitored patients for 
excessive bone loss or multiple fractures, and women who 
met either criterion were again counseled about alternative 
treatment options.
Nevertheless, the evidence provided by this study 
suggests that a once-yearly infusion of ZOL during a 3-year 
period signiﬁ  cantly reduced the risk of hip fractures in this 
particular population.
Zoledronic acid and mortality
The second major trial is the HORIZON recurrent fracture 
trial.30 This well designed trial in a population of frail older 
subjects constitutes the ﬁ  rst trial of an osteoporosis interven-
tion to show a reduction in mortality. This 3-year, multi-
center, multinational, double-blind, placebo-controlled trial 
of 2127 patients with a recent hip fracture assessed the effect 
of ZOL administered within 90 days after surgical repair. Men 
and women 50 years of age or older were eligible for inclusion 
within 90 days after surgical repair of a hip fracture sustained 
with minimal trauma (ie, a fall from standing height or a lower 
height). All patients who were enrolled in the trial had under-
gone repair of a hip fracture and were unable or unwilling to 
take an oral bisphosphonate. Additional enrollment criteria 
included being ambulatory before the hip fracture and having 
both legs. Concomitant therapy with nasal calcitonin, selective 
estrogen-receptor modulators, hormone replacement, tibolone, 
and external hip protectors was allowed at the discretion of 
the investigator. Previous use of bisphosphonates or parathy-
roid hormone was allowed after a washout period that varied 
according to the drug and the duration of its use. Previous use 
of strontium or sodium ﬂ  uoride was not allowed. Any patient 
with a serum 25-hydroxyvitamin D level of 15 ng/mL or 
less, or if the level was not available, a loading dose of either 
vitamin D3 or D2 (at a dose of 50,000 to 125,000 IU) was 
given orally or intramuscularly 14 days before the ﬁ  rst infusion 
of ZOL. Thereafter, all patients received daily supplementa-
tion with oral calcium (1000 to 1500 mg) and vitamin D (800 
to 1200 IU). Exclusion criteria were previous hypersensitivity 
to a bisphosphonate, a potential for pregnancy, a calculated 
creatinine clearance of less than 30 mL per minute, a corrected 
serum calcium level of more than 11.0 mg/dL (2.8 mmol/L) 
or less than 8.0 mg/dL (2.0 mmol/L), active cancer, metabolic 
bone disease other than osteoporosis, and a life expectancy 
of less than 6 months in the investigator’s judgment. BMD Clinical Interventions in Aging 2009:4 161
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at the hip and femoral neck and the calculated creatinine 
clearance were determined at baseline and annually. The 
primary endpoint was the incidence of further hip fractures 
and secondary endpoints included the change in BMD in the 
nonfractured hip, new vertebral fractures, and pre-speciﬁ  ed 
safety endpoints, including death.
Of a total of 2127 patients, 1065 patients were randomly 
assigned to receive ZOL, and 1062 patients were assigned 
to receive placebo; 71.3% of the patients completed the 
trial. The median follow-up time was 1.9 years. Baseline 
demographic and clinical characteristics were similar in the 
two groups, with 41.8% of patients having a T score less 
than –2.5 SD at the femoral neck.
At 24 months ZOL was associated with a rate of new 
clinical fractures of 8.6%, as compared with 13.9% in the 
placebo group, an absolute risk reduction of 5.3% and 
a relative reduction of 35%. Among patients who had a 
fracture, the mean time to clinical fracture was 39.8 months 
in the ZOL group and 36.4 months in the placebo group. The 
risk reduction was very similar in the intention-to-treat and 
per-protocol populations. The rates of new clinical vertebral 
and nonvertebral fractures were signiﬁ  cantly lower (1.7% vs 
3.8% and 7.6% vs 10.7%, respectively).
However the incidence of new hip fractures was not 
significantly different (2.0% vs 3.5%, a nonsignificant 
reduction in relative risk of 30%) (Figure 2B). Although in 
a post hoc analysis, signiﬁ  cant divergence in the fracture-
free survival curves between the two groups for all clinical 
fractures was seen as early as 12 months (p = 0.02 by the log-
rank test). BMD at the total hip increased in the ZOL group 
by 2.6%, 4.7%, 5.5% at 12, 24 and 36 months respectively 
compared with a decline BMD in the placebo group by 1.0%, 
0.7%, and 0.9%, respectively. BMD at the femoral neck 
also increased in the ZOL group by 0.8%, 2.2% and 3.6% at 
12, 24 and 36 months respectively and declined in the placebo 
group by 1.7%, 2.1%, and 0.7%, respectively over the same 
period. All increases in BMD were statistically signiﬁ  cant 
compared with placebo. Finally, the difference in delayed 
union of fractured bone between the two study groups was 
not signiﬁ  cant (3.2% in the ZOL group and vs 2.7% in the 
placebo group; 95% CI, 0.72 to 1.90; p = 0.61).
In the safety analysis, mortality rates were similar in the 
ﬁ  rst 12 months but were signiﬁ  cantly different at 24 months 
with 9.6% in the ZOL group vs 13.3% in the placebo group 
(a relative reduction of 28% in the risk of death) (Figure 2C). 
The causes of deaths were primarily from cardiovascular and 
cerebrovascular diseases. Serious adverse events occurred 
with similar frequency in the two groups (38.3% in the ZOL 
group and 41.2% in the placebo group). More patients in 
the ZOL group than in the placebo group reported pyrexia, 
myalgia, bone pain, and musculoskeletal pain. More patients 
in the placebo group (11.4%) reported having fallen than 
in the ZOL group (9.7%). The incidence of cardiovascular 
events was similar in the two groups. A total of 24 patients in 
the ZOL group (2.3%) and 39 patients in the placebo group 
(3.7%) had a serious adverse event of arrhythmia; rates of AF 
were similar in the two groups 1.1% vs 1.3%. The incidence 
of renal adverse events was similar in the two study groups, 
including events among patients with a baseline creatinine 
clearance of 30 to 60 mL per minute.
Although no speciﬁ  c case-ﬁ  nding effort was made, no 
cases of ONJ were reported. In summary, this is a well 
conducted trial showing that treatment efﬁ  cacy is possible in 
the frail elderly group in whom oral bisphosphonates is less 
efﬁ  cacious due to side effects and noncompliance. In addition, 
the reduction in number of deaths is almost the same as the 
reduction in number of fractures suggesting that fewer post 
fracture deaths are unlikely to account for the beneﬁ  t seen.62 
Whether concomitant treatment with calcitonin, selective 
estrogen-receptor modulators, and hormone-replacement 
therapy had an effect on the results is also not certain. 
However when this study was designed, the only therapies 
that had been proven to reduce the risk of hip fractures were 
alendronate and risedronate.63–65 Thus, it is likely that the use 
of nonbisphosphonate therapies did not have an important 
inﬂ  uence on the overall outcome. In addition the study by 
Black et al29 did not show any difference in the incidence of 
hip, nonvertebral, or all clinical fractures between subjects 
who received, and those who did not receive, concomitant 
therapy (10% in both study groups).
For the mortality results, it is more likely that the reason 
for this reduction in mortality is multifactorial62 as suggested 
by the separation of the mortality curves occurring after a 
year; however, further investigation and more detailed analy-
sis of these data may be needed to elucidate the reasons. It 
is also interesting that despite the reduction in hip fracture 
not reaching statistical signiﬁ  cance the number needed to 
treat of 67 to 71 is quite comparable to other bisphosphonate 
trials.29,63 The baseline risk of death in this patient population 
was substantially different from that in previous ZOL trials29 
and may also account for some of the variance in results. In 
addition, the study was not powered to show the differences 
between treatment groups for this end point.
Special comments should also be made regarding the inci-
dence of AF. Although an increased rate of AF in association 
with this medication had been a concern in the HORIZON Clinical Interventions in Aging 2009:4 162
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trial,29 it is interesting that in this study, the incidence did not 
differ between the medication and placebo groups.
Zoledronic acid in the older 
population
Although the evidence supporting ZOL as a choice for the 
prevention of osteoporosis fractures in older patients is 
scarce, there are several characteristics of ZOL that make it 
an appealing choice in this population.
In terms of compliance, several studies have demon-
strated that older patients are more prone to discontinue their 
treatment after 6 months of administration due to several 
reasons including difﬁ  culties with the strict instructions 
required for oral bisphosphonates, the lack of symptoms 
associated with osteoporosis and the poor encouragement 
received from their family practitioners to continue with their 
treatment.66–68 In this situation, ZOL constitutes an important 
choice since it only requires 1 dose every year. Nevertheless, 
the patients should continue taking vitamin D and calcium 
in a permanent manner.
A second argument in favor of ZOL in older patients is 
the recent evidence showing that additionally to its effect on 
re-fracturing, patients receiving ZOL showed lower mortality 
rates.30 This is a particularly important effect especially in 
the older and frail populations. However, the mechanisms 
that explain this effect remain unknown.
Finally, no studies have been pursued in long-term insti-
tutions looking at the effectiveness and cost-beneﬁ  t of ZOL 
in institutionalized elderly patients. For patients that are in 
long-term care institutions, the population at higher risk of 
fractures according to the literature,18,69 ZOL could become 
an important choice for fracture prevention.
Conclusion
Hip fractures are an increasing global problem as the 
population ages. The human costs and economic burden 
will escalate proportionately. Pharmacotherapy to reduce 
the morbidity and mortality associated with hip fractures 
is effective and proven although is still limited by conve-
nience, tolerability and thus compliance. Decisions regarding 
which agent should be based on these factors and sound hip 
fracture data. Only alendronate,70 risedronate71 and ZOL29,30 
have been proven to reduce nonvertebral and in particularly 
hip fractures in the intention to treat populations from more 
than one trial and randomized controlled trials of at least 
3 years’ duration.65 ZOL offers advantages of convenience, 
tolerability and thus greater compliance. The ﬁ  ndings that 
ZOL reduces the recurrence of fractures in patients who 
already sustained a hip fracture and increase survival, means 
that there is now available therapy for a population that 
was largely without therapy before these recent trials were 
pursued.
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